Collectively, these results suggest that elevated SIGLEC12 expression promotes an immune-activated and inflammatory microenvironment, whereas the low-expression state may correspond to reduced immune engagement and impaired antigen presentation, possibly influencing tumor immune evasion and therapy responsiveness. The gene discussed is SIGLEC12; the disease is neoplasm.